Trials / Conditions / Congenital Hyperinsulinism

Congenital Hyperinsulinism

22 registered clinical trials studyying Congenital Hyperinsulinism — 4 currently recruiting.

Status	Trial	Sponsor	Phase
Active Not Recruiting	RZ358 Treatment for Congenital Hyperinsulinism NCT06208215	Rezolute	Phase 3
Recruiting	HM15136 (Efpegerglucagon) Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI NCT04732416	Hanmi Pharmaceutical Company Limited	Phase 2
Recruiting	18F-DOPA II - PET Imaging Optimization NCT04706910	University of Alberta	Phase 3
Completed	Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism NCT04172441	Zealand Pharma	Phase 2 / Phase 3
Completed	An Open-Label Multiple Dose Study of RZ358 in Patients With Congenital Hyperinsulinism NCT04538989	Rezolute	Phase 2
Active Not Recruiting	Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyper NCT03941236	Zealand Pharma	Phase 3
Completed	A Two-Period Open-label Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyper NCT03777176	Zealand Pharma	Phase 3
Unknown	GLP-1 Receptor Expression in CHI NCT03768518	Radboud University Medical Center	—
Completed	18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety NCT03042416	University of Alberta	Phase 3
Withdrawn	Pasireotide in Hyperinsulinemic Hypoglycemia NCT03053284	Montefiore Medical Center	Phase 2
Recruiting	18FluoroLDOPA PET Imaging for the Detection and Localization of Focal Congenital Hyperinsulinism NCT04205604	Miguel Pampaloni	Phase 2
Completed	CSI-Glucagon for Prevention of Hypoglycemia in Children With Congenital Hyperinsulinism NCT02937558	Xeris Pharmaceuticals	Phase 2
Completed	A Single-Dose Open-Label Study of XOMA 358 in Subjects With Congenital Hyperinsulinism NCT02604485	XOMA (US) LLC	Phase 2
Recruiting	Fluorodopa F 18 in Congenital Hyperinsulinism and Insulinoma NCT02021604	Cook Children's Health Care System	Phase 1
Completed	Lanreotide Autogel Treatment of Patients With Congenital Hyperinsulinism of Infancy NCT01070758	Sheba Medical Center	Phase 4
Terminated	Effect of Exendin (9-39) on Glucose Requirements to Maintain Euglycemia NCT00835328	Diva De Leon	Phase 1 / Phase 2
Completed	Effect of Exendin-(9-39) on Fasting Adaptation and Protein Sensitivity NCT00897676	Diva De Leon	Phase 1 / Phase 2
Completed	Sandostatine® LP and Hyperinsulinism NCT00987168	Assistance Publique - Hôpitaux de Paris	Phase 2
Completed	Effect of Exendin-(9-39) on Glycemic Control in Subjects With Congenital Hyperinsulinism NCT00571324	Diva De Leon	Phase 1 / Phase 2
Completed	Utility of [F-18] fluoroDOPA for Neonatal Hyperinsulinism NCT00674440	Children's Hospital of Philadelphia	Phase 2
No Longer Available	Compassionate Use of SOM230 for Hyperinsulinemic/Hypoglycemia NCT02835131	Montefiore Medical Center	—
No Longer Available	Study of the Use of [18F]-DOPA in Hyperinsulinemic Hypoglycemia NCT02533219	Baylor College of Medicine	—